Premal H. Thaker

Premal H. Thaker, MD, MS

  • Gynecologic Oncology
  • Obstetrics & Gynecology

Sees Patients For

Gynecologic oncology, endometrial cancer, vulvar carcinoma, cervical cancer, ovarian cancer, adnexal masses, tumors, hysterectomy, ob/gyn, women's health, lymphadenectomy, endometrial adenocarcinomas, cervical intraepithelial neoplasia, laparoscopy, gynecologic malignancies

Patients Seen At

Hospital Affiliations

  • Barnes-Jewish Hospital
  • Missouri Baptist Medical Center
  • Progress West Hospital

Board Certifications

  • Gynecologic Oncology
  • Obstetrics and Gynecology

Academic Title(s)

Professor, Obstetrics and Gynecology
Director, Gynecological Oncology Clinical Research
Division of Gynecologic Oncology

Languages

  • English

Education

Fellowship

2006 Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Residency

2002 Obstetrics and Gynecolgy, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

M.S.

2004 Cancer Biology, University of Texas Graduate School of Biomedical Sciences, Houston, Texas

Medical Degree

1997 Allegheny University-Medical College of PA, Philadelphia, Pennsylvania

B.A.

1995 Biology, Villanova University, Villanova, Pennsylvania

Publications & Research

Search PubMed for publications »

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

Company Name: CelsionRoyalties: $1 - $9,999Equity: YesConsulting/Advisory Board: $10,000 - $19,999Speaker Fees: $1 - $9,999Reporting Date: 05/01/2020
Company Name: TesaroRoyalties: $1 - $9,999Equity: NoConsulting/Advisory Board: $1 - $9,999Speaker Fees: $10,000 - $19,999Reporting Date: 05/01/2020
Company Name: Merck & CorporationRoyalties: $1 - $9,999Equity: NoConsulting/Advisory Board: $1 - $9,999Speaker Fees: $10,000 - $19,999Reporting Date: 05/01/2020
Company Name: AstraZenecaRoyalties: $1 - $9,999Equity: NoConsulting/Advisory Board: $1 - $9,999Speaker Fees: $60,000 - $79,999Reporting Date: 05/01/2020